Education
About Us
Working with TipRanks
Follow Us
Definium Therapeutics (DFTX)
NASDAQ:DFTX
Top Page
Definium Therapeutics
(NASDAQ:DFTX)
Select Model
Select Model
Rating:60Neutral
Price Target:
$18.50
▲(4.88% Upside)
Action:ReiteratedDate:02/28/26
The score is driven by a mixed fundamental setup: strong balance sheet/cash runway and encouraging late-stage trial momentum from the earnings call support the outlook, while the lack of revenue, widening losses, and accelerating cash burn materially constrain the financial performance score. Technicals are supportive with an established uptrend, but valuation is difficult to justify using standard metrics given negative earnings and no dividend.
Positive Factors
Late-stage pipeline momentum
Having multiple pivotal Phase III readouts scheduled across 2026 materially strengthens the company’s path to demonstrating clinical efficacy and unlocking regulatory and commercial milestones. Durable because successful readouts can convert a development-stage R&D model into a de-risked regulatory pathway and enable long-term commercialization plans.
Voyage SSRE shows high statistical power
A blinded sample-size re-estimation showing much lower variance and >99% power reduces the probability of an inconclusive result and lowers the chance of needing additional enrollment. This structural trial robustness improves the odds of definitive Phase III evidence and reduces timeline and funding risk tied to trial extensions.
Strong cash position and runway
A sizable cash balance and guidance of runway into 2028 provides durable funding to complete pivotal trials, invest in commercial readiness, and engage regulators without immediate capital raises. This enhances strategic optionality and reduces near-term financing pressure, allowing focus on clinical execution and regulatory interactions.
Negative Factors
Pre-revenue with widening net losses
The company remains pre-revenue while net losses have widened materially year-over-year, creating a persistent profitability gap. Over the medium term this constrains return metrics, increases reliance on financing, and limits internal reinvestment capacity unless pivotal trial results convert into revenue or partnerships.
Negative operating cash flow and rising cash burn
Accelerating cash burn and consistently negative operating cash flow structurally increase financing needs and dilution risk if timelines slip. Even with current runway, continued high spend on Phase III and commercial build means capital planning remains a persistent fundamental vulnerability over the next 2–3 years.
Binary clinical and regulatory risk
Business viability and the transition to commercial revenue hinge on binary Phase III outcomes and regulatory decisions. Even with strong design and Phase II signals, Phase III or FDA interactions can produce unfavorable outcomes, making long-term cash returns and strategy highly contingent on a few critical trial results.
Definium Therapeutics (DFTX) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$1.76B
Dividend YieldN/A
Average Volume (3M)1.47M
Price to Earnings (P/E)―
Beta (1Y)1.62
Revenue GrowthN/A
EPS Growth0.69%
CountryUS
Employees74
SectorHealthcare
Sector Strength45
IndustryMedical - Pharmaceuticals
Share Statistics
EPS (TTM)-0.51
Shares Outstanding99,698,130
10 Day Avg. Volume1,724,268
30 Day Avg. Volume1,469,436
Financial Highlights & Ratios
PEG Ratio-0.19
Price to Book (P/B)3.60
Price to Sales (P/S)0.00
P/FCF Ratio-9.09
Enterprise Value/Market Cap0.85
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-8.85
Forecast
1Y Price Target
$37.27Price Target Upside111.28% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering11
EPS Forecast (FY)-1.94
Revenue Forecast (FY)N/A
Definium Therapeutics Business Overview & Revenue Model
Company DescriptionDefinium Therapeutics, Inc. is a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company’s lead product candidates include MM120, which is in phase 3 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and MM402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase I clinical trials for the treatment of core symptoms of autism spectrum disorder. Mind Medicine (MindMed) Inc. is headquartered in New York, New York.
How the Company Makes MoneyMind Medicine makes money through a revenue model that primarily involves research and development activities aimed at creating marketable psychedelic-inspired therapeutics. The company's key revenue streams are anticipated to come from the successful commercialization of its drug candidates, which are currently under various stages of clinical trials. Additional revenue could be generated through strategic partnerships with pharmaceutical companies, licensing agreements, and collaborations with research institutions. MindMed may also explore opportunities for grants and government funding to support its research initiatives. However, as a biotech company still in the development phase, substantial revenue generation is contingent upon regulatory approval and market acceptance of its therapeutic products.
Definium Therapeutics Earnings Call Summary
Earnings Call Date:Feb 26, 2026
(Q4-2025)
| % Change Since: |
Next Earnings Date:May 07, 2026
Earnings Call Sentiment Positive
The call emphasized clear operational and clinical progress: multiple pivotal trials on track with strong enrollment, a favorable blinded SSRE in Voyage that suggests high statistical power, supportive Phase II efficacy data (published in JAMA), an expanded commercial and leadership team, and a strengthened balance sheet with cash runway into 2028. These positives are tempered by substantial y/y expense increases and a larger net loss, dependence on upcoming pivotal results and regulatory interactions, and the absence of disclosed long-term open-label durability data to date. Overall, the company appears well-capitalized and operationally prepared entering a data-rich 2026, but material clinical and regulatory outcomes remain pending.Q4-2025 Updates
Positive Updates
Late-Stage Pipeline Momentum and Upcoming Catalysts
Three Phase III readouts expected in 2026. Emerge (first pivotal MDD) is fully enrolled with top-line data expected in late Q2 2026. Voyage (GAD) is ~80% enrolled with top-line expected in early Q3 2026. Panorama (second GAD) is rapidly progressing with top-line expected in H2 2026. Ascend (second MDD) has site activation completed and first dosing anticipated by early Q2 2026.
Statistical Confidence from Voyage Blinded SSRE
Voyage blinded sample size re-estimation required no increase in enrollment. Observed model-based standard deviation on HAM-A was 6.7 vs the planned 10, and non-evaluable rate was 10% vs the assumed 15%, implying >99% power to detect a 5-point HAM-A difference and a minimum detectable difference <2 points if parameters hold.
Strong Phase II Clinical Efficacy Evidence
Phase IIb (published in JAMA) showed placebo-adjusted improvements of 7.7 points (HAM-A) and 6.4 points (MADRS) at week 12. Absolute reductions included a 21.9-point HAM-A decrease (48% remission, 65% response) and an 18.7-point MADRS decrease — metrics management cites as potentially best-in-class versus existing anxiolytics/antidepressants.
Financial Position and Runway
Cash, cash equivalents and investments were $411.6M at December 31, 2025 vs $273.7M at year-end 2024, an increase of $137.9M (+50.4%). Management believes this cash runway is sufficient to fund operations into 2028.
Balance Sheet Strength and Share Price Appreciation
Management noted a change in fair value of financing warrants of $22.8M driven by stock price appreciation from $6.96 to $13.39 (≈+92.5% year-over-year), reflecting investor interest as the company advances toward pivotal readouts.
Commercial Readiness and Organizational Build
Commercial infrastructure expanded: new Chief Commercial Officer (joined March 2025), assembled commercial leadership in marketing, market access and operations, REMS/scheduled-drug experience, and a hub/"white-glove" launch strategy planned. Analyst Day scheduled April 22 for further commercial detail.
Pipeline Expansion: DT402 for Autism Spectrum Disorder
DT402 (R-enantiomer of MDMA) Phase IIa study initiated (single-dose open-label) after completion of Phase I single-ascending dose study; first participant dosed and initial data expected later in 2026. Program targets core social communication deficits in ASD.
Operational Efficiencies and Enrollment Execution
Faster-than-expected site activations and DEA approvals reported (weeks), ability to fast-track sites that participated in Emerge, and improved non-evaluable/dropout metrics (Voyage interim non-evaluable rate 10% vs ~25% in Phase II), supporting rapid enrollment and retention.
Negative Updates
Substantial Year-over-Year Expense Increases
R&D expenses rose to $117.7M in 2025 from $65.3M in 2024, an increase of $52.4M (+80.2%), driven primarily by higher DT120 program spend (+$44.7M) and internal personnel costs (+$9.3M). General and administrative expenses increased to $48.6M from $38.6M (+$10.0M, +25.9%).
Widening Net Loss
Net loss increased to $183.8M for 2025 from $108.7M in 2024, a rise of $75.1M (+69.1%). Management attributes part of the year-over-year net loss impact to a $22.8M change in fair value of financing warrants (non-cash) driven by stock price appreciation.
Outcome and Regulatory Risk Remain
Key commercial and valuation inflection points depend on pending pivotal readouts (Emerge, Voyage, Panorama, Ascend). Management acknowledged forward-looking uncertainty and that filing/approval strategy will depend on the eventual strength of the data and further interactions with FDA.
Limited Public Data on Long-Term (Part B) Results
Part B (40-week open-label extension) durability and retreatment data have not yet been disclosed; management has not committed to a timeline for presenting Part B results and will share when sufficient aggregated data are available.
Potential for Phase III Delta Compression Risk
While management has taken design/operational steps to limit it, they acknowledged the common industry risk that Phase III placebo-adjusted deltas can compress versus Phase II; therefore, actual Phase III placebo-adjusted separation remains a critical unknown until readouts.
Company Guidance
The company guided to a data‑rich 2026, with 3 pivotal Phase III readouts expected this year: Emerge (MDD) is fully enrolled with topline data anticipated in late Q2; Ascend (second MDD) expects first dosing in early Q2 and targets ~175 participants randomized 2:1:2 (100 µg / 50 µg / placebo); Voyage (GAD) is ~80% enrolled (target ~200 randomized 1:1) with topline expected in early Q3 and its blinded sample‑size re‑estimation complete (first 100 completers showed a model SD of 6.7 vs an assumed 10 and a non‑evaluable rate of 10% vs an assumed 15%, implying >99% power to detect a 5‑point HAM‑A difference and a minimum detectable difference <2 points); Panorama (GAD) targets ~250 randomized 2:1:2 with topline in H2 2026 and an update to be provided at the April 22 Analyst Day. Phase III design: MDD primary endpoint is change in MADRS at week 6 (80% power to detect a 5‑point difference for 100 µg vs placebo); GAD primary endpoint is change in HAM‑A at week 12 (90% power to detect a 5‑point difference). They reiterated Phase IIb benchmarks (placebo‑adjusted improvements of 7.7 HAM‑A and 6.4 MADRS at week 12, absolute reductions of 21.9 HAM‑A and 18.7 MADRS with 48% remission and 65% response) and said ongoing FDA engagement under Breakthrough Therapy supports an efficient NDA path subject to positive readouts. Financial guidance: 2025 R&D $117.7M and G&A $48.6M, net loss $183.8M, cash, cash equivalents and investments $411.6M (projected runway into 2028).Definium Therapeutics Financial Statement Overview
Summary
Pre-revenue profile with widening losses (net loss about -$184M in 2025 vs. about -$109M in 2024) and increasing cash burn (FCF about -$132M in 2025 vs. about -$79M in 2024). Offsetting positives include a stronger, low-debt balance sheet (debt $0; equity about $332M) and expanded assets, but the business remains reliant on external funding until clinical milestones translate into revenue.Income Statement
The company has generated no revenue across the reported annual periods, while losses have remained substantial (net loss worsening to about -$184M in 2025 vs. about -$109M in 2024). Profitability is consistently negative, and the lack of a revenue base makes it difficult to show operating leverage or margin improvement; the main positive is that the business appears to be investing for growth typical of a development-stage pharma profile, but near-term earnings visibility remains weak.12
Very Negative
Balance Sheet
Balance sheet leverage is low: total debt is $0 in 2025 (down from about $21.9M in 2024), and equity is sizable at about $332M in 2025. Assets also expanded meaningfully (about $440M in 2025 vs. about $302M in 2024), suggesting improved funding capacity; however, returns on equity are deeply negative due to ongoing losses, and continued cash burn could pressure equity over time if additional financing is needed.62
Positive
Cash Flow
Cash generation remains a key weakness: operating cash flow and free cash flow are negative every year, with cash burn increasing to about -$132M in 2025 from about -$79M in 2024. A positive free cash flow growth figure in 2025 reflects a change versus the prior year, but absolute cash flow is still meaningfully negative, implying ongoing reliance on external funding until revenue-producing milestones are achieved.24
Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | -527.00K | -3.16M | 0.00 | 0.00 |
| EBITDA | -178.31M | -105.87M | -92.57M | -63.15M | -91.24M |
| Net Income | -183.79M | -108.68M | -95.73M | -56.80M | -93.04M |
Balance Sheet | |||||
| Total Assets | 440.10M | 302.15M | 124.54M | 169.99M | 164.00M |
| Cash, Cash Equivalents and Short-Term Investments | 411.59M | 273.74M | 99.70M | 142.14M | 133.54M |
| Total Debt | 0.00 | 21.85M | 14.13M | 72.00K | 0.00 |
| Total Liabilities | 107.77M | 60.70M | 46.41M | 19.08M | 12.34M |
| Stockholders Equity | 332.33M | 241.45M | 78.13M | 150.92M | 151.66M |
Cash Flow | |||||
| Free Cash Flow | -131.56M | -79.13M | -64.36M | -50.14M | -45.82M |
| Operating Cash Flow | -131.56M | -79.13M | -64.36M | -50.14M | -45.82M |
| Investing Cash Flow | -151.61M | 0.00 | 0.00 | 0.00 | -297.00K |
| Financing Cash Flow | 267.27M | 253.20M | 21.85M | 59.05M | 98.82M |
Definium Therapeutics Technical Analysis
Positive
17.64
Price Trends
16.78
Positive
14.58
Positive
11.97
Positive
Market Momentum
0.46
Positive
55.64
Neutral
48.76
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For DFTX, the sentiment is Positive. The current price of 17.64 is below the 20-day moving average (MA) of 17.74, above the 50-day MA of 16.78, and above the 200-day MA of 11.97, indicating a bullish trend. The MACD of 0.46 indicates Positive momentum. The RSI at 55.64 is Neutral, neither overbought nor oversold. The STOCH value of 48.76 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for DFTX.
Definium Therapeutics Risk Analysis
Definium Therapeutics disclosed 75 risk factors in its most recent earnings report. Definium Therapeutics reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 3 New Risks
1.
We may plan to grow and develop our business through in-license agreements, acquisitions of or investment in new or complementary businesses, product candidates or technologies, and the failure to manage these license agreements, acquisitions or investments, or the failure to integrate them with our existing business, could have a material adverse effect on us. Q4, 2025
2.
We may develop or license intellectual property for which development was funded or otherwise assisted by, the U.S. government and/or government agencies, such as the National Institutes of Health, for development of our technology and product candidates. Failure to meet our own obligations to future licensors or upstream licensors, including such government agencies, may result in the loss of our rights to such intellectual property, which could harm our business. Q4, 2025
3.
bodies may require additional data, including with respect to abuse potential of our product candidates, before allowing us to commence a clinical trial or before approving any future marketing application we may submit. Q4, 2025
Definium Therapeutics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
61 Neutral | $1.63B | -8.42 | -24.22% | ― | ― | 3.18% | |
60 Neutral | $1.76B | -6.51 | -84.39% | ― | ― | 0.69% | |
58 Neutral | $2.05B | -13.06 | -34.75% | ― | ― | -17.01% | |
57 Neutral | $1.86B | -101.81 | 1813.84% | ― | 196.42% | 53.92% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | $999.01M | -3.70 | -186.06% | ― | ― | ― | |
45 Neutral | $1.37B | -1.64 | -688.89% | ― | ― | 18.76% |
* Healthcare Sector Average
DFTX
Definium Therapeutics
17.64
10.94
163.28%
ANAB
AnaptysBio
64.72
48.28
293.67%
ELVN
Enliven Therapeutics
27.25
6.36
30.45%
TYRA
Tyra Bioscience
38.05
26.89
240.95%
BHVN
Biohaven Ltd.
9.09
-19.66
-68.38%
INBX
Inhibrx Biosciences Inc
68.69
54.69
390.64%
Definium Therapeutics Corporate Events
Executive/Board Changes
Definium Therapeutics Expands Board, Appoints New Director
Neutral
Jan 29, 2026
On January 28, 2026, Definium Therapeutics, Inc. expanded its board of directors from six to seven members and appointed Roger Adsett to the newly created seat, with his term effective January 29, 2026 and running until the company’s 2026 annual general meeting or until a successor is chosen. Adsett, who was not assigned to any board committees at the time of appointment, will receive annual cash compensation of $40,000 under the company’s non-employee director compensation policy and an option to purchase 50,000 common shares that vests over time subject to his continued board service, reflecting a standard governance and incentive structure with no related-party arrangements or disclosable transactions reported in connection with his selection.
The most recent analyst rating on (DFTX) stock is a Buy with a $20.00 price target. To see the full list of analyst forecasts on Definium Therapeutics stock, see the DFTX Stock Forecast page.
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.